Project Grant R56AI189343
Award Date
6/17/25
Completion Date
5/31/26
Dollars Obligated
$920K
Federal Agency
National Institute of Allergy and Infectious Diseases
Awardee
Emmune Inc. (N65ZDYUGWAH8)
Federal Grant Program
93.855
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $486,057 to The Trustees of the University of Pennsylvania to develop a novel mRNA gene therapy approach to address challenges in achieving an HIV cure. The research aims to design three mRNA-based interventions: CD4-targeted delivery of the viral protein Tat to drive HIV-1 transcription, hepatic delivery of mRNA...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $769,737 to Yale University to develop capsid-engineered adeno-associated viral (AAV) vectors that can specifically target and deliver gene therapies to human T cells and myeloid cells. The goal is to use these AAV vectors to deliver a designer recombinase called BREC1, which can eliminate HIV provirus integrated in...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to Emmune Inc. to conduct pre-clinical IND-enabling studies for their long-acting recombinant protein therapeutic, ECD4-IG, as a treatment for HIV. The key products and services to be delivered through this award include in vitro assays required for an Investigational New Drug (IND) application submission,...
The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $2,688,880 Project Grant to Emory University to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products and services to be delivered under this grant include: Comprehensive testing of the effects of IL-15/IL-15RA therapy combined with TGF-beta blockade on different T and NK cell...
This $800,389 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), will fund research to evaluate the safety and therapeutic potential of a novel strategy towards a cure for HIV infection. The key products or services to be delivered include: Comprehensive testing of the effects of IL-15/IL-15RA-FC therapy combined with TGF-beta blockade (Galunisertib) on different T and NK cell...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $194,616 to Emory University for the development of virus-like particles (VLPs) to support HIV-1 cure strategies. The key objectives are to: 1) Use VLPs to deliver the HIV-1 Tat protein as a latency reversing agent to reactivate latent HIV-1 proviruses, and 2) Utilize VLPs to deliver the Cas12k enzyme fused to HIV-1...
This Project Grant award for $1,314,572.00, provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research aimed at developing a cure strategy for HIV-1 using CD4-mimetic compounds (CD4MCs) and CD4-induced antibodies (CD4I Abs). The research, conducted by Yale University, leverages the recent discovery of a new class of indoline CD4MCs that display improved antiviral potency and breadth...
This $343,744 project grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a comprehensive strategy for an Investigational New Drug (IND) application for a novel hematopoietic stem/progenitor cell-based chimeric antigen receptor (CAR) gene therapy approach to treat HIV infection. The primary objectives are to: 1) develop a comprehensive product development strategy...
This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is focused on enhancing the persistence of CD4CAR T-cell therapies to treat HIV infection. The $186,408 award will support research to characterize and overcome the inhibitory effects of soluble HIV antigen on CD4CAR T-cell function, as well as strategies to extend the persistence of these therapeutic T cells using the IL15...
This Project Grant award, funded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), aims to develop a novel HIV cure strategy by targeting CD127-expressing tissue reservoir cells. The total funding amount is $250,791.00, with an award date of August 6, 2024 and an ultimate completion date of July 31, 2026. The key products and services to be delivered under this grant include: Utilizing an ex vivo...